Safety and efficacy evaluation of pertuzumab in patients with solid tumors - Test2 - elhamkhani - TriplyDB

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

http://www.wikidata.org/entity/Q33714388

about

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

http://www.wikidata.org/entity/Q33714388

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@ast

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@en

type

label

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@ast

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@en

prefLabel

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@ast

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@en

P1433

Q33714388-0CEE562F-BC32-42E1-8E45-298F8DB4EE98

P1476

Q33714388-A1A24F69-D116-40A0-B495-70D59B393B0B

P2093

Q33714388-4ADB844C-8324-4F02-A9CC-8029CAF58B84

Q33714388-4B0A8890-FDDE-4C38-A365-4B573CB2EA39

Q33714388-5A6B8AFB-44CE-42C5-B2DD-B1569223380B

Q33714388-910D04B2-AF3C-4FB7-A098-400E96A92C45

Q33714388-E22A27E4-AA46-4E14-AF5A-E7AE6E36E3A5

Q33714388-E8D34A4F-E84E-4E01-AD70-FD1DEC433192

P275

Q33714388-6CDC0A42-5428-4D2B-AC58-490A13ABF944

P2860

Q33714388-0521B237-EF07-4B7D-B9A0-ECCC03C87077

Q33714388-12D2CC82-5F7E-47E6-9284-26B729B4591B

Q33714388-1491F82C-3819-4115-B649-D77C549FFF69

Q33714388-1A1C9F9E-6A48-46C5-8CEF-7B0BA3340452

Q33714388-1C137C77-A35A-4AC2-A8FD-CC1F1B9ABC04

Q33714388-1F5687F8-6BD2-41B5-8D9F-4907764FABED

Q33714388-234044C5-ACC9-4A83-BBE6-601D023F2624

Q33714388-294D228A-1698-40FA-A717-DBD7A95AAD6F

Q33714388-2AACDE33-853E-4646-AE19-730361E82ED7

Q33714388-3BEF018E-E3C9-49FA-A981-DD6451891EE0

P304

Q33714388-83F0FEE5-B1FE-4F08-92C8-0D7225BF453A

P31

Q33714388-4DEB956D-C163-4FD8-B19E-56B104FBB9FF

Q33714388-65DBC027-D8E5-4E7A-932F-2530B6305CFA

Q33714388-80ee451d-cefb-414d-9321-24d2e00bb7fa

P356

Q33714388-EB831993-6E49-4900-AE9F-9C2A97CA0CB9

P407

Q33714388-4EE90289-5C94-40E7-B4F3-EA2FF26ACB1B

P433

Q33714388-7A684E73-EF2E-476A-851C-C3AA5DE4213E

P478

Q33714388-79A02650-4038-456E-8631-9C5BB695097D

P5008

Q33714388-01A65CA0-17A7-43A5-B135-A5CF0D34D084

P577

Q33714388-9178FE18-1287-47A2-A5CE-EA773F76CCDC

P698

Q33714388-DED9AE36-BA3C-496B-909F-8EA1CD71561D

P921

Q33714388-1D31476D-AC67-404D-A980-8676A9D73E35

Q33714388-200FF0EE-490E-403C-8DC2-70E270930360

Q33714388-73088557-88D7-4A75-876C-CA06DFAEDC33

Q33714388-FC39C293-20DB-4978-9EFC-DAED384148F1

P932

Q33714388-8E6C4AF7-8304-4205-89D8-6DE840958312

P356

MD.0000000000006870

P1433

P1476

Safety and efficacy evaluation of pertuzumab in patients with solid tumors

@en

P2093

Chenjing Zhu

http://www.w3.org/2001/XMLSchema#string

Hui Gao

http://www.w3.org/2001/XMLSchema#string

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Kai Shen

http://www.w3.org/2001/XMLSchema#string

Wenwu Ling

http://www.w3.org/2001/XMLSchema#string

Xuelei Ma

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NoDerivs 4.0 International

P2860

Global cancer statistics

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Cancer statistics, 2014

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative me

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

P304

e6870

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000006870

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2017-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28514302

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

P932

5440139

http://www.w3.org/2001/XMLSchema#string